[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614259":3},{"organization":4,"outcomesModule":7,"designInfo":47,"detailedDescription":11,"studyPopulation":11,"armGroups":53,"interventions":69,"overallOfficials":11,"centralContacts":91,"locations":100,"responsibleParty":400,"collaborators":11,"id":402,"slug":403,"hasResults":404,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":11,"eligibilityCriteria":408,"healthyVolunteers":404,"sex":409,"minAge":410,"maxAge":11,"enrollmentInfo":411,"targetDuration":11,"studyType":414,"phases":415,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":103,"whyStopped":11,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":436},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":11},[9,13,15,17],{"measure":10,"description":11,"timeFrame":12},"Number of participants with adverse events (AEs), Serious AEs (SAEs), AE of special interest (AESIs) and AEs leading to dose modifications",null,"Up to approximately 31 weeks",{"measure":14,"description":11,"timeFrame":12},"Number of participants with AEs, SAEs, AESIs, and AEs leading to dose modifications by severity",{"measure":16,"description":11,"timeFrame":12},"Number of participants with dose limiting toxicities (DLTs)",{"measure":18,"description":11,"timeFrame":12},"Number of participants with clinically significant changes in Vital Signs, Body Weight, Laboratory Tests [Hematology, Clinical Chemistry, Urinalysis], Cardiac Function [ECG], and Eastern Cooperative Oncology Group (ECOG) performance status",[20,23,25,27,29,32,35,38,41,44],{"measure":21,"description":11,"timeFrame":22},"Plasma concentration of GSK5764227 [conjugated antibody and payload (GSK5757810)","Up to approximately 112 weeks",{"measure":24,"description":11,"timeFrame":22},"Number of participants with anti-drug antibody (ADA) against GSK5764227",{"measure":26,"description":11,"timeFrame":22},"Number of participants with neutralising antibody (NAb) against GSK5764227",{"measure":28,"description":11,"timeFrame":22},"Titer of ADA against GSK5764227",{"measure":30,"description":31,"timeFrame":22},"Objective Response Rate (ORR)","ORR is defined as the proportion of participants who have achieved best observed response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by investigator, according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for Cohort A or per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) for Cohort B.",{"measure":33,"description":34,"timeFrame":22},"Disease control Rate (DCR18)","DCR18 is defined as the proportion of participants who have achieved CR or PR, or stable disease (SD) of ≥17 weeks as assessed by investigator according to PCWG3 for Cohort B.",{"measure":36,"description":37,"timeFrame":22},"Duration of Response (DoR)","DOR is defined as the time from the date of the first documented objective response (CR\u002FPR) as assessed by investigator according to RECIST 1.1 for cohort A or PCWG3 for cohort B, until the date of the first documented disease progression (PD) or death due to any cause, whichever is earlier.",{"measure":39,"description":40,"timeFrame":22},"Progression free survival (PFS)","PFS is defined as the time from the date of first dose until the earliest date of documented disease progression as assessed by investigator according to RECIST 1.1 for cohort A.",{"measure":42,"description":43,"timeFrame":22},"Radiographic progression-free survival (rPFS)","rPFS is defined as the time from the date of first dose until the earliest date of documented PD per PCWG3-modified RECIST 1.1 (soft tissue lesion assessment) and\u002For PCWG3 bone lesion assessment for cohort B or death due to any cause.",{"measure":45,"description":46,"timeFrame":22},"Prostate-specific antigen 50 (PSA50)","PSA50 is defined as percentage of participants with a decrease of \\>=50% in the PSA concentration from the baseline PSA value, confirmed at least 3 weeks later (cohort B)",{"allocation":48,"interventionModel":49,"interventionModelDescription":11,"primaryPurpose":50,"observationalModel":11,"timePerspective":11,"maskingInfo":51},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":52,"maskingDescription":11,"whoMasked":11},"NONE",[54,60,65],{"label":55,"type":56,"description":11,"interventionNames":57},"Metastatic colorectal cancer (mCRC) cohort A1","EXPERIMENTAL",[58,59],"Drug: GSK5764227","Drug: Bevacizumab",{"label":61,"type":56,"description":11,"interventionNames":62},"Metastatic colorectal cancer (mCRC) cohort A2",[58,59,63,64],"Drug: Fluorouracil","Drug: leucovorin",{"label":66,"type":56,"description":11,"interventionNames":67},"Metastatic castration-resistant prostate cancer (mCRPC) cohort B",[58,68],"Drug: Enzalutamide",[70,75,79,83,87],{"type":71,"name":72,"description":73,"armGroupLabels":74,"otherNames":11},"DRUG","GSK5764227","Participants will receive GSK5764227.",[66,55,61],{"type":71,"name":76,"description":77,"armGroupLabels":78,"otherNames":11},"Bevacizumab","Participants will receive bevacizumab.",[55,61],{"type":71,"name":80,"description":81,"armGroupLabels":82,"otherNames":11},"Fluorouracil","Participants will receive fluorouracil.",[61],{"type":71,"name":84,"description":85,"armGroupLabels":86,"otherNames":11},"leucovorin","Participants will receive leucovorin.",[61],{"type":71,"name":88,"description":89,"armGroupLabels":90,"otherNames":11},"Enzalutamide","Participants will receive enzalutamide.",[66],[92,97],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":98,"role":94,"phone":99,"phoneExt":11,"email":96},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[101,123,137,151,165,179,195,208,222,235,251,264,278,288,298,313,326,336,346,359,374,387],{"facility":102,"status":103,"city":104,"state":105,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":114,"contacts":115},"GSK Investigational Site","RECRUITING","Reunion","Florida","34747-4606","United States","US",{"type":110,"coordinates":111},"Point",[112,113],-81.60813,28.28029,{"lat":113,"lon":112},[116,117,120],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":121,"role":122,"phone":11,"phoneExt":11,"email":11},"Guru Sonpavde","PRINCIPAL_INVESTIGATOR",{"facility":102,"status":103,"city":124,"state":125,"zip":126,"country":107,"countryCode":108,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"New Hyde Park","New York","11042-1118",{"type":110,"coordinates":128},[129,130],-73.68791,40.7351,{"lat":130,"lon":129},[133,134,135],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":136,"role":122,"phone":11,"phoneExt":11,"email":11},"Geraldine O'Sullivan Coyne",{"facility":102,"status":103,"city":138,"state":139,"zip":140,"country":107,"countryCode":108,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Philadelphia","Pennsylvania","19107",{"type":110,"coordinates":142},[143,144],-75.16362,39.95238,{"lat":144,"lon":143},[147,148,149],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":150,"role":122,"phone":11,"phoneExt":11,"email":11},"Babar Bashir",{"facility":102,"status":103,"city":152,"state":153,"zip":154,"country":107,"countryCode":108,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Nashville","Tennessee","37203",{"type":110,"coordinates":156},[157,158],-86.78444,36.16589,{"lat":158,"lon":157},[161,162,163],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":164,"role":122,"phone":11,"phoneExt":11,"email":11},"Benjamin Garmezy",{"facility":102,"status":103,"city":166,"state":167,"zip":168,"country":107,"countryCode":108,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Dallas","Texas","75230",{"type":110,"coordinates":170},[171,172],-96.80667,32.78306,{"lat":172,"lon":171},[175,176,177],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":178,"role":122,"phone":11,"phoneExt":11,"email":11},"Reva Schneider",{"facility":102,"status":103,"city":180,"state":181,"zip":182,"country":183,"countryCode":184,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Douglas","Queensland","4814","Australia","AU",{"type":110,"coordinates":186},[187,188],146.75234,-19.32394,{"lat":188,"lon":187},[191,192,193],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":194,"role":122,"phone":11,"phoneExt":11,"email":11},"Jun Beng Kong",{"facility":102,"status":103,"city":196,"state":181,"zip":197,"country":183,"countryCode":184,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Tugun","4224",{"type":110,"coordinates":199},[200,201],153.5,-28.15,{"lat":201,"lon":200},[204,205,206],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":207,"role":122,"phone":11,"phoneExt":11,"email":11},"David Martin",{"facility":102,"status":103,"city":209,"state":210,"zip":211,"country":183,"countryCode":184,"cosmosGeoPoint":212,"geoPoint":216,"contacts":217},"Geelong","Victoria","3220",{"type":110,"coordinates":213},[214,215],144.36069,-38.14711,{"lat":215,"lon":214},[218,219,220],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":221,"role":122,"phone":11,"phoneExt":11,"email":11},"Caitlin Murphy",{"facility":102,"status":103,"city":223,"state":11,"zip":224,"country":183,"countryCode":184,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"Bendigo","VIC 3550",{"type":110,"coordinates":226},[227,228],144.28024,-36.75818,{"lat":228,"lon":227},[231,232,233],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":234,"role":122,"phone":11,"phoneExt":11,"email":11},"Samuel Harris",{"facility":102,"status":103,"city":236,"state":237,"zip":238,"country":239,"countryCode":240,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"Ottawa","Ontario","K1H 8L6","Canada","CA",{"type":110,"coordinates":242},[243,244],-75.69812,45.41117,{"lat":244,"lon":243},[247,248,249],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":250,"role":122,"phone":11,"phoneExt":11,"email":11},"John Hilton",{"facility":102,"status":103,"city":252,"state":237,"zip":253,"country":239,"countryCode":240,"cosmosGeoPoint":254,"geoPoint":258,"contacts":259},"Toronto","M5G 2M9",{"type":110,"coordinates":255},[256,257],-79.39864,43.70643,{"lat":257,"lon":256},[260,261,262],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":263,"role":122,"phone":11,"phoneExt":11,"email":11},"Abdulazeez Salawu",{"facility":102,"status":103,"city":265,"state":11,"zip":266,"country":267,"countryCode":11,"cosmosGeoPoint":268,"geoPoint":272,"contacts":273},"Seoul","03722","South Korea",{"type":110,"coordinates":269},[270,271],126.9784,37.566,{"lat":271,"lon":270},[274,275,276],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":277,"role":122,"phone":11,"phoneExt":11,"email":11},"Sang Joon Shin",{"facility":102,"status":103,"city":265,"state":11,"zip":279,"country":267,"countryCode":11,"cosmosGeoPoint":280,"geoPoint":282,"contacts":283},"06351",{"type":110,"coordinates":281},[270,271],{"lat":271,"lon":270},[284,285,286],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":287,"role":122,"phone":11,"phoneExt":11,"email":11},"Seung-Tae Kim",{"facility":102,"status":103,"city":265,"state":11,"zip":289,"country":267,"countryCode":11,"cosmosGeoPoint":290,"geoPoint":292,"contacts":293},"138-736",{"type":110,"coordinates":291},[270,271],{"lat":271,"lon":270},[294,295,296],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":297,"role":122,"phone":11,"phoneExt":11,"email":11},"Jae Lyun Lee",{"facility":102,"status":103,"city":299,"state":11,"zip":300,"country":301,"countryCode":302,"cosmosGeoPoint":303,"geoPoint":307,"contacts":308},"Barcelona","08035","Spain","ES",{"type":110,"coordinates":304},[305,306],2.15899,41.38879,{"lat":306,"lon":305},[309,310,311],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":312,"role":122,"phone":11,"phoneExt":11,"email":11},"Guzman Alonso Casal",{"facility":102,"status":103,"city":314,"state":11,"zip":315,"country":301,"countryCode":302,"cosmosGeoPoint":316,"geoPoint":320,"contacts":321},"Madrid","28034",{"type":110,"coordinates":317},[318,319],-3.70256,40.4165,{"lat":319,"lon":318},[322,323,324],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":325,"role":122,"phone":11,"phoneExt":11,"email":11},"Teresa Alonso Gordoa",{"facility":102,"status":103,"city":314,"state":11,"zip":327,"country":301,"countryCode":302,"cosmosGeoPoint":328,"geoPoint":330,"contacts":331},"28040",{"type":110,"coordinates":329},[318,319],{"lat":319,"lon":318},[332,333,334],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":335,"role":122,"phone":11,"phoneExt":11,"email":11},"Bernard Doger",{"facility":102,"status":103,"city":314,"state":11,"zip":337,"country":301,"countryCode":302,"cosmosGeoPoint":338,"geoPoint":340,"contacts":341},"28050",{"type":110,"coordinates":339},[318,319],{"lat":319,"lon":318},[342,343,344],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":345,"role":122,"phone":11,"phoneExt":11,"email":11},"Juan José Soto",{"facility":102,"status":103,"city":347,"state":11,"zip":348,"country":301,"countryCode":302,"cosmosGeoPoint":349,"geoPoint":353,"contacts":354},"Málaga","29010",{"type":110,"coordinates":350},[351,352],-4.42034,36.72016,{"lat":352,"lon":351},[355,356,357],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":358,"role":122,"phone":11,"phoneExt":11,"email":11},"Javier García Corbacho",{"facility":102,"status":103,"city":360,"state":11,"zip":361,"country":362,"countryCode":363,"cosmosGeoPoint":364,"geoPoint":368,"contacts":369},"Leicester","LE1 5WW","United Kingdom","UK",{"type":110,"coordinates":365},[366,367],-1.13169,52.6386,{"lat":367,"lon":366},[370,371,372],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":373,"role":122,"phone":11,"phoneExt":11,"email":11},"Harriet Walter",{"facility":102,"status":103,"city":375,"state":11,"zip":376,"country":362,"countryCode":363,"cosmosGeoPoint":377,"geoPoint":381,"contacts":382},"London","W12 0NN",{"type":110,"coordinates":378},[379,380],-0.12574,51.50853,{"lat":380,"lon":379},[383,384,385],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":386,"role":122,"phone":11,"phoneExt":11,"email":11},"David Pinato",{"facility":102,"status":103,"city":388,"state":11,"zip":389,"country":362,"countryCode":363,"cosmosGeoPoint":390,"geoPoint":394,"contacts":395},"Sutton","SM2 5PT",{"type":110,"coordinates":391},[392,393],-0.2,51.35,{"lat":393,"lon":392},[396,397,398],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},{"name":118,"role":94,"phone":119,"phoneExt":11,"email":96},{"name":399,"role":122,"phone":11,"phoneExt":11,"email":11},"Alec Paschalis",{"type":401,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100614259","phase-1-a-study-of-gsk5764227-in-combination-with-standard-of-care-soc-or-other-agents-in-participants-with-advanced-solid-tumors-100614259",false,"NCT07277270","A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors","A Phase 1b\u002F2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose.\n* Has adequate organ function.\n* Has histologically confirmed unresectable adenocarcinoma or unresectable metastatic adenocarcinoma of the colon or rectum. (Cohort A)\n* Histologically or cytologically confirmed adenocarcinoma of the prostate (Cohort B)\n\nExclusion Criteria:\n\n* Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas \\[e.g., breast, cervix, bladder\\] that have been resected with no evidence of disease.\n* Has had any major surgery within 28 days prior to first dose.\n* Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.\n* Has serious infection within 4 weeks prior to the first dose,\n* Has untreated brain or central nervous system (CNS) metastases or brain\u002FCNS metastases that have progressed\n* Any evidence of current interstitial lung disease (ILD) or pneumonitis OR a prior history of ILD requiring high-dose glucocorticoids or non-infectious pneumonitis requiring high-dose glucocorticoids.\n* Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening.\n* Has received immunosuppressive agents within 30 days prior to first dose of study intervention (or requires long-term \\[30 days or longer\\]). Low-dose corticosteroids (prednisone ≤10 milligrams (mg)\u002Fday or equivalent) may be administered.","ALL","18 Years",{"count":412,"type":413},83,"ESTIMATED","INTERVENTIONAL",[416],"PHASE1","The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.",[419],"Neoplasms",[421,422,423,72,76,80,424,88,425,426],"Solid Tumors","Metastatic colorectal cancer","Metastatic castration-resistant prostate cancer","Folinic acid","EMBOLD","EMBOLD PanTumor-102","2026-09-23",{"date":429,"type":430},"2026-09-25","ACTUAL",{"date":432,"type":430},"2025-12-03",{"date":434,"type":413},"2030-05-01",{"name":5,"class":6},22]